KeyZell

Company snapshot

KeyZell is a biotechnology company focused on transforming how cancer and complex diseases are addressed. We integrate cutting-edge science, pharmaceutical development, and advanced technology to accelerate therapies with real impact for patients. Our approach combines precision oncology, drug repositioning, and medical artificial intelligence platforms, with a strong clinical and regulatory focus

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for KeyZell. Not investment advice.

• What is KeyZell?

  Amzell is a pharma organization headquartered in CN. Primary therapeutic focus areas include Osteoarthritis of Knee. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. P

• Is KeyZell publicly traded?

  KeyZell appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does KeyZell develop or market?

  We link 1 drug profile(s) where KeyZell is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/amzell#company-drugs.

• What are the latest developments for KeyZell?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does KeyZell focus on?

  KeyZell focuses on Osteoarthritis of Knee based on our analysis of their pipeline programs and drug development activities.